Streetbeat News

Analyst Ratings

ALPN

Over the past 3 months, 4 analysts have published their opinion on Alpine Immune Sciences (NASDAQ:ALPN) stock. The average price target is $16.75, implying an upside from the current price of $12.67. This average price target has increased by 19.64% over the past month.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 1:00 pm

CRWD

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on CrowdStrike Holdings (NASDAQ:CRWD) and raises the price target from $182 to $185.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 1:00 pm

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) has received 9 bullish ratings from analysts in the last quarter, with an average 12-month price target of $39.0. The ratings have remained unchanged from the previous quarter.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 1:00 pm

SRAD

Sportradar Gr (NASDAQ:SRAD) has received 5 bullish and 3 indifferent analyst ratings in the last quarter. The average 12-month price target for the stock, according to 8 analysts, is $13.44, up 5.0% from the previous average of $12.80. The high and low price targets are $15.00 and $11.50 respectively.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 1:00 pm

MLTX

MoonLake (NASDAQ:MLTX) has received mostly bullish ratings from analysts in the last quarter, with an average price target of $64.45, indicating potential upside from the current price of $56.19. The average price target has increased by 56.43% from the previous average of $41.20.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 1:00 pm

CHWY

RBC Capital analyst Steven Shemesh has maintained an 'Outperform' rating on Chewy (NYSE:CHWY), but lowered the price target from $56 to $44.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 12:59 pm

CTLT

RBC Capital analyst Sean Dodge has reiterated an Outperform rating on Catalent (NYSE:CTLT) and maintained a $58 price target.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 12:58 pm

BF

RBC Capital analyst Nik Modi has maintained a 'Sector Perform' rating on Brown Forman Inc Class B Common Stock (NYSE:BF) and lowered the price target from $68 to $67.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 12:58 pm

BMO

RBC Capital analyst Darko Mihelic has reiterated an 'Outperform' rating on Bank of Montreal (TSX:BMO), but lowered the price target from C$143 to C$138.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 12:57 pm

CRM

Stifel analyst Parker Lane maintains a 'Buy' rating on Salesforce (NYSE:CRM) and raises the price target from $250 to $275.

Portfolio Pulse from Benzinga Newsdesk

August 31, 2023 | 12:56 pm